A panel of experts that advises the Centers for Disease Control and Prevention on vaccine policy will not meet as previously ...

Prior to vaccine availability, RSV was a significant cause of illness and hospitalization in older adults in the U.S., ...

A study today in JAMA Network Open from the University of California, San Francisco (UCSF), shows a high uptake of respiratory syncytial virus (RSV) vaccine and the RSV-preventing monoclonal antibody ...

Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

Vermont has the second lowest state fatality rate in the US (145.3 per 100K; Hawaii 112.6/100K). Mississippi (461.9/100K) and ...

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

Moderna MRNA announced fourth-quarter 2024 results. Though earnings and sales beat estimates, both metrics declined ...

The respiratory syncytial virus (RSV) vaccine triggered strong immune responses among people aged 60 years and older during ...

The approvals come as Robert F. Kennedy Jr.—who has been critical of vaccines—takes leadership of the Department of Health ...

GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for ...

Every fall and winter, the United States sees an uptick in the number of people who fall ill to influenza and other seasonal diseases. This flu season typically stretches from October to ...

Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...